Sonoma Pharmaceuticals (SNOA) Non-Current Deffered Revenue (2011 - 2025)
Sonoma Pharmaceuticals (SNOA) posted quarterly Non-Current Deffered Revenue of $24000.0 for Q2 2025, down 62.5% year-over-year from $64000.0 in Q2 2024, and down 67.12% quarter-over-quarter from $73000.0 in Q1 2025.
Sonoma Pharmaceuticals (SNOA) Non-Current Deffered Revenue (2011 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Non-Current Deffered Revenue history runs 15 years deep, the most recent figure standing at $24000.0 for Q2 2025.
- In Q2 2025, Non-Current Deffered Revenue fell 62.5% year-over-year to $24000.0; the TTM figure through Jun 2025 stood at $24000.0 (down 62.5% YoY), while the FY2025 annual figure was $73000.0, down 77.88% from the prior year.
- Non-Current Deffered Revenue for Q2 2025 stood at $24000.0, down from $73000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $330000.0 in Q1 2024, with the low at $24000.0 in Q2 2025.
- The 5-year median for Non-Current Deffered Revenue is $139000.0 (2022), against an average of $146444.4.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue jumped 135.71% in 2024, then plunged 77.88% in 2025.
- Sonoma Pharmaceuticals' Non-Current Deffered Revenue stood at $190000.0 in 2021, then slumped by 32.63% to $128000.0 in 2022, then slipped by 21.09% to $101000.0 in 2023, then sank by 70.3% to $30000.0 in 2024, then slipped by 20.0% to $24000.0 in 2025.
- Business Quant data shows SNOA's Non-Current Deffered Revenue at $24000.0 in Q2 2025, $73000.0 in Q1 2025, and $30000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 73,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Sep 30, 2024 | 179,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 330,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Sep 30, 2023 | 114,000.00 |
| Jun 30, 2023 | 132,000.00 |
| Mar 31, 2023 | 140,000.00 |
| Dec 31, 2022 | 128,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Jun 30, 2022 | 152,000.00 |
| Mar 31, 2022 | 182,000.00 |
| Dec 31, 2021 | 190,000.00 |
| Sep 30, 2021 | 205,000.00 |
| Jun 30, 2021 | 225,000.00 |
| Mar 31, 2021 | 229,000.00 |
| Dec 31, 2020 | 251,000.00 |
| Sep 30, 2020 | 235,000.00 |